Polosa 2014b.
Study characteristics | ||
Methods | Design: Prospective cohort study Recruitment: Volunteers, leaflets, cessation service kiosk in hospital Setting: Smoking cessation clinic, Italy Study start date: January 2013; Study end date: November 2013 |
|
Participants | Total N: 50 Inclusion criteria:
Exclusion criteria:
40% women, mean age 41, mean cpd 25, mean FTND 6.0 No EC use at baseline, not motivated to quit |
|
Interventions |
EC: Refillable 2nd generation devices (personal vaporisers ‐ PVs): EGO/CE4 model, filled with tobacco aroma e‐Liquid containing 9 mg/ml nicotine; instructed to use the study products ad libitum (up to a maximum of 5 ml/day; i.e. half vial) Behavioural support: Participants were instructed how to charge, fill, activate and use the EC. Key troubleshooting was addressed and phone numbers were supplied for assistance. “No emphasis on encouragement, motivation and reward for the smoking cessation‐related efforts were provided during the study.” |
|
Outcomes | 4, 8, 12 and 24 weeks 30‐day PP verified by CO ≤ 10 ppm Adverse events Cpd, exhaled CO, reduction rates, product usage, and opinions of the EC products |
|
Study funding | "The authors wish to thank FlavourArt (Oleggio, NO, Italy; www.flavourart.it). Authors wish to thank LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti Smoking League) for supporting this research" | |
Author declarations | "RP has received lecture fees and research funding from Pfizer and GlaxoSmithKline, manufacturers of stop smoking medications. He has also served as a consultant for Pfizer and Arbi Group Srl, an Italian distributor of e‐Cigarettes. RP is currently scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti Smoking League). PC, MM, JBM, and CR have no relevant competing interest to declare in relation to this work" |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | High risk | Not controlled |
Allocation concealment (selection bias) | High risk | Not controlled |
Incomplete outcome data (attrition bias) All outcomes | Low risk | 76% followed up, ITT analysis used, no significant differences in baseline characteristics between completers and those lost to follow‐up |
Selective reporting (reporting bias) | Unclear risk | Unable to determine prespecified outcomes |